Healthcare professionals discuss the vital role of pharmacy teams in managing complex patient care, emphasizing collaboration and medication safety. In this episode, ‘The Role of Pharmacy in ...

Surgeons at Cleveland Clinic completed the first commericial procedure using the Hugo robot-assisted surgery system in the US. The first US commercial surgical case using the Hugo robot-assisted ...

Boxed warnings were removed from Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva, spanning progestogen-only, systemic estrogen-only, topical vaginal estrogen, and combined systemic ...

The approval is supported by data from the phase 3 AMPLITUDE trial.

Amy Pearlman, MD, sits down with Katherine A. Amin, MD, to discuss the evolving landscape of female pelvic medicine, overactive bladder management, and fellowship training.

Dr Hamstra describes the three FDA-approved rectal spacers SpaceOAR, Barrigel, and BioProtect, noting differences in placement technique, advantages, potential risks, and the need for long-term ...

A new analysis supports return to widespread screening. A reevaluation of the tradeoffs of prostate cancer screening using the most recent data should rewrite the negative narrative associated with ...

In a retrospective study of almost 500 men, the use of hyaluronic acid filler for penile girth enhancement appeared safe with limited adverse events. Using the PhalloFILL system, a novel hyaluronic ...

The AUA/CUA/SUFU guide focuses on a combination of symptoms and positive cultures. Uncomplicated urinary tract infection is one of the most common indications for antimicrobial exposure in otherwise ...

UGN-102's NDA is supported by the phase 3 ENVISION trial, showing a 79.6% complete response rate at 3 months for LG-IR-NMIBC patients. The FDA is evaluating if the observed duration of response is due ...

The Altaviva device offers a minimally invasive treatment for urge urinary incontinence, with patients returning home with therapy activated. It features a 15-year battery lifespan, MRI compatibility, ...

"We've been doing a lot of work at Johns Hopkins using high-dose testosterone therapies to treat patients with metastatic prostate cancer," says Mark C. Markowski, MD, PhD. In this interview, Mark C.